Antigen Presentation to Self-reactive T Cells in Human Autoimmune Diseases
人类自身免疫性疾病中抗原呈递给自身反应性 T 细胞
基本信息
- 批准号:8316141
- 负责人:
- 金额:$ 33.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-01 至 2013-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAffinityAntigen PresentationAntigen-Presenting CellsAutoantigensAutoimmune DiseasesAutoimmune ProcessAutoimmunityBindingBiochemicalCD4 Positive T LymphocytesChimeric ProteinsElementsEventExperimental Autoimmune EncephalomyelitisFundingGoalsHLA-DR2 AntigenHumanImageIncidenceInvestigationKineticsLeadModelingMyelinN-terminalPatientsPeptide antibodiesPeptide/MHC ComplexPeptidesPropertyRelapseSignal PathwaySignal TransductionSignaling MoleculeStromal CellsStructureSynapsesT-LymphocyteTCR ActivationThymus GlandTransgenic MiceViralbaseimmunological synapseimmunological synapse formationlymph nodesperipheral tolerancesynaptogenesistargeted delivery
项目摘要
The goal of the project is to define the antigen presentation and T cell recognition mechanisms
responsible for the activation of myelin-specific CD4 T cells in MS. During this funding period, the Pi's lab
determined the crystal structure of the first human autoimmune TCR and identified an unusual TCR binding
topology. Biochemical studies demonstrated a low affinity interaction of this TCR with its self-peptide/MHC
complex, consistent with the suboptimal binding mode observed in the structure. Such a suboptimal binding
mode may facilitate escape from tolerance induction in the thymus and periphery because the relevant
antigen presenting cells express limiting quantities of self-antigen. Transgenic mice that express this TCR
and the human MHC restriction element nevertheless develop spontaneous autoimmunity at a high
incidence, indicating that these T cells have recognition/signaling mechanisms that at least partially
compensate for the altered TCR interaction with self-peptide/MHC. Imaging studies demonstrated
substantial differences in the organization of immunological synapses formed by two different myelin-specific
human T cell clones compared to two anti-viral T cell clones.
During the next funding period, we will determine how the altered TCR recognition properties affect the
formation of immunological synapses and resulting signaling events. In Aim 1, we will define the
mechanisms of immunological synapse formation by examining the kinetics of synapse formation, the
recruitment of key signaling molecules, the duration of signaling as well as the mechanisms that terminate
signaling by TCR internalization. Our hypothesis is that the suboptimal TCR binding properties delay TCR
transport to the synapse center where TCR is internalized, thus extending the duration of the initially weaker
activation signal. In Aim 2, we will examine how these changes quantitatively modify the contribution of
particular signaling pathways in self-reactive versus anti-viral T cells, with the goal of identifying signaling
molecules that are critical for the activation of self-reactive T cells but dispensable for anti-viral T cells. In
Aim 3, we will examine whether tolerance can nevertheless be induced for such T cells by targeted delivery
of the self-peptide via an antibody-peptide fusion protein to lymph node stromal cells specialized in
peripheral tolerance.
该项目的目标是确定抗原呈递和T细胞识别机制
负责MS中髓鞘特异性CD 4 T细胞的激活。在此资助期间,Pi的实验室
确定了第一个人类自身免疫性TCR的晶体结构,并鉴定了一种不寻常的TCR结合,
topology.生物化学研究表明,这种TCR与其自身肽/MHC的低亲和力相互作用
复合物,与结构中观察到的次优结合模式一致。这种次优的绑定
模式可能有助于逃避胸腺和外周的耐受诱导,
抗原呈递细胞表达有限量的自身抗原。表达这种TCR的转基因小鼠
而人MHC限制性元件仍然以高水平发展自发性自身免疫,
发病率,表明这些T细胞具有识别/信号传导机制,至少部分
补偿改变的TCR与自身肽/MHC的相互作用。成像研究表明
由两种不同的髓鞘特异性神经元形成的免疫突触组织的实质性差异
人T细胞克隆与两种抗病毒T细胞克隆的比较。
在下一个融资期间,我们将确定更改后的TCR确认属性如何影响
免疫突触的形成和由此产生的信号事件。在目标1中,我们将定义
免疫突触形成的机制通过检查突触形成的动力学,
关键信号分子的募集,信号传导的持续时间以及终止的机制
通过TCR内化的信号传导。我们的假设是,次优TCR结合特性延迟TCR
TCR被转运到突触中心,在那里TCR被内化,从而延长了最初较弱的免疫反应的持续时间。
激活信号在目标2中,我们将研究这些变化如何定量地改变
自身反应性T细胞与抗病毒T细胞中的特定信号传导途径,目的是识别信号传导
这些分子对于自身反应性T细胞的活化至关重要,但对于抗病毒T细胞却至关重要。在
目的3,我们将研究是否仍然可以通过靶向递送诱导对这样的T细胞的耐受性
通过抗体-肽融合蛋白将自身肽的抗体-肽融合到淋巴结基质细胞中,
外周耐受性
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kai W Wucherpfennig其他文献
Cracking the code of human T-cell immunity
破解人类 T 细胞免疫的密码
- DOI:
10.1038/nbt.2626 - 发表时间:
2013-07-09 - 期刊:
- 影响因子:41.700
- 作者:
Christopher J Harvey;Kai W Wucherpfennig - 通讯作者:
Kai W Wucherpfennig
4-1bb Enrichment Enhances Adoptive T Cell Therapy for Hematological Malignancies Using a Novel Approach for Ex Vivo Immune Cell Priming with DC/Tumor Fusion Vaccine
- DOI:
10.1182/blood-2023-182381 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Kathrine S Rallis;Jessica Liegel;Giulia Cheloni;Poorva Bindal;Isabella Saldarriaga;Junyan Zhang;Georges Chedid;Joseph Abirached;John G. Clohessy;Sophia Adamia;Kai W Wucherpfennig;Donald Kufe;Jacalyn Rosenblatt;David Avigan - 通讯作者:
David Avigan
Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1
- DOI:
10.1182/blood-2024-200876 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
Prateek Pophali;Giulia Cheloni;Richard M. Stone;Kai W Wucherpfennig;Aric C. Hall;Amir T. Fathi;Lina Bisharat;Emma K Logan;Yiwen Liu;Donna S. Neuberg;Malgorzata McMasters;Jessica Liegel;Jacqueline S. Garcia;Daniel J. DeAngelo;Michele Narcis;Dina Stroopinsky;Pavania Elavalakanar;Ioannis S Vlachos;Ilene A. Galinsky;Jason Pyrdol - 通讯作者:
Jason Pyrdol
Advances in CD137-Enriched Adoptive T Cell Therapy for Acute Myeloid Leukemia Via Ex Vivo Immune Cell Priming with DC/AML Fusion Vaccine
- DOI:
10.1182/blood-2024-208563 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
Kathrine S Rallis;Jessica Liegel;Giulia Cheloni;Poorva Bindal;Isabella Saldarriaga;Junyan Zhang;Georges Chedid;Joseph Abirached;Jonah Lee;John G. Clohessy;Samprity Ankita;Rajeev Relangi;Lina Bisharat;Hazal Toros;Sophia Adamia;Jasper B Lee;Donald Kufe;Kai W Wucherpfennig;Jacalyn Rosenblatt;David Avigan - 通讯作者:
David Avigan
Kai W Wucherpfennig的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kai W Wucherpfennig', 18)}}的其他基金
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
MICA 免疫逃避的治疗靶向 - NKG2D 通路
- 批准号:
10380449 - 财政年份:2021
- 资助金额:
$ 33.27万 - 项目类别:
Core 1: Tumor Processing and Single Cell RNA sequencing Core
核心1:肿瘤处理和单细胞RNA测序核心
- 批准号:
10210225 - 财政年份:2020
- 资助金额:
$ 33.27万 - 项目类别:
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
靶向三阴性乳腺癌的主要免疫逃避途径
- 批准号:
10029035 - 财政年份:2020
- 资助金额:
$ 33.27万 - 项目类别:
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials
项目。
- 批准号:
10210221 - 财政年份:2020
- 资助金额:
$ 33.27万 - 项目类别:
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
靶向三阴性乳腺癌的主要免疫逃避途径
- 批准号:
10224146 - 财政年份:2020
- 资助金额:
$ 33.27万 - 项目类别:
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
靶向三阴性乳腺癌的主要免疫逃避途径
- 批准号:
10400167 - 财政年份:2020
- 资助金额:
$ 33.27万 - 项目类别:
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials
项目。
- 批准号:
10477984 - 财政年份:2020
- 资助金额:
$ 33.27万 - 项目类别:
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
靶向三阴性乳腺癌的主要免疫逃避途径
- 批准号:
10668947 - 财政年份:2020
- 资助金额:
$ 33.27万 - 项目类别:
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials
项目。
- 批准号:
10684029 - 财政年份:2020
- 资助金额:
$ 33.27万 - 项目类别:
Core 1: Tumor Processing and Single Cell RNA sequencing Core
核心1:肿瘤处理和单细胞RNA测序核心
- 批准号:
10684050 - 财政年份:2020
- 资助金额:
$ 33.27万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 33.27万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 33.27万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 33.27万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 33.27万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 33.27万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 33.27万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 33.27万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 33.27万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 33.27万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 33.27万 - 项目类别:
Continuing Grant